Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Chris Gemmiti is the VP of Operations at Sentien Biotech, a clinical-stage company using mesenchymal stem cells in an extracorporeal bioreactor to treat systemic inflammatory diseases. Previously, Chris had roles at Harvard University’s Wyss Institute and at Organogenesis, the latter at which he led the approval of the first CBER-approved allogeneic cell therapy in 2012. Chris has his PhD in Biomedical Engineering from Georgia Tech.